Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes

Oncogene. 2008 May 15;27(22):3165-75. doi: 10.1038/sj.onc.1210975. Epub 2007 Dec 10.

Abstract

Five breast cancer subtypes have been described in sporadic breast cancer (SBC) using expression arrays: basal-like, ERBB2, normal breast-like, luminal A and B. These molecular subtypes show different genomic aberration patterns (GAPs). Recently, our group described these breast cancer subtypes in 50 non-BRCA1/2 familial tumors using immunohistochemistry assays. We extended this study to the other classes of familial breast cancer (FBC), including 62 tumors (18 BRCA1, 16 BRCA2 and 28 non-BRCA1/2), with the same panel of 25 immunohistochemical (IHC) markers and histological grade obtaining a similar classification. We combined these data with results generated by a 1 Mb BAC array-based CGH study to evaluate the genomic aberrations of each group. We found that BRCA1-related tumors are preferentially basal-like, whereas non-BRCA1/2 familial tumors are mainly luminal A subtype. We described distinct GAPs related to each IHC subtype. Basal tumors had a greater number of gains/losses, while luminal B tumors had more high-level DNA amplifications. Our data are similar to those obtained in SBC studies, highlighting the existence of distinct genetic pathways of tumor evolution, common to both SBC and FBC.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Biomarkers, Tumor / metabolism
  • Breast Neoplasms / classification*
  • Breast Neoplasms / genetics*
  • Breast Neoplasms / metabolism
  • Chromosome Aberrations*
  • Chromosomes, Human, Pair 8
  • Cluster Analysis
  • Family
  • Female
  • Gene Amplification
  • Gene Expression Profiling*
  • Gene Expression Regulation, Neoplastic
  • Gene Frequency
  • Genes, BRCA1
  • Genes, BRCA2
  • Genetic Heterogeneity
  • Humans
  • Immunohistochemistry
  • Male
  • Middle Aged
  • Oligonucleotide Array Sequence Analysis

Substances

  • Biomarkers, Tumor